Issue Date: July 20, 2009
Abbott And GSK Join For Cancer Diagnostic
Abbott Laboratories and GlaxoSmithKline will develop an automated molecular diagnostic test that uses polymerase chain reaction (PCR) technology to screen non-small-cell lung cancer tumors for expression of the MAGE-A3 antigen. MAGE-A3 is a tumor-specific antigen that is expressed in non-small-cell lung cancer and other cancer types. GSK currently has a MAGE-A3 antigen-specific cancer immunology candidate in Phase III development. "Through this partnership, we aim to make MAGE-A3 testing of lung tumors available in standard pathology labs around the world," says Vincent Brichard, head of immunotherapeutics at GSK.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society